

Striving for Consensus: Optimizing the Current and Future Management of Biliary Tract Cancers

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase II HERB trial evaluated the efficacy of which agent for HER2-expressing biliary tract cancers?**
 - a. Datopotamab deruxtecan
 - b. Trastuzumab deruxtecan**
 - c. Trastuzumab and pertuzumab
 - d. Tucatinib and trastuzumab
 - e. Zanidatamab
- 2. Which of the following best describes the mechanism of action of brigimadlin?**
 - a. EGFR monoclonal antibody
 - b. HER2-directed antibody-drug conjugate
 - c. Irreversible FGFR2 inhibitor
 - d. MDM2-p53 antagonist**
- 3. Which of the following is the most common adverse event associated with FGFR inhibitors such as pemigatinib and futibatinib?**
 - a. Anemia
 - b. Stomatitis
 - c. Hyperphosphatemia**
 - d. Thrombocytopenia
- 4. What was the dose of T-DXd administered to patients enrolled in the DESTINY-PanTumor02 study?**
 - a. 4.5 mg/kg Q3W
 - b. 5.4 mg/kg Q3W**
 - c. 6.4 mg/kg Q3W
 - d. 6.5 mg/kg Q3W
- 5. Which of the following was added to first-line chemotherapy for patients with advanced biliary cancers in the Phase III TOPAZ-1 study?**
 - a. Infigratinib
 - b. Pemigatinib
 - c. Durvalumab**
 - d. Ivosidenib